Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — FY2025 Earnings Presentation
30 slides from Onward Medical's earnings presentation, Mar 31, 2026
Slide 1: Investor Webcast: FY25 Results and Business Update
Investor Webcast FY25 Results and Business Update March 31, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be “forward-looking statements”. These forward- looking statements may be identified by the use of forward-looking terminology, includi
Slide 3: Speaking Today
Speaking Today Dave Marver Ali Kiboro Shari O’Quinn Chief Executive Officer Chief Financial Officer Chief Clinical, Regulatory & Quality Officer March 2026 Webcast 3
Slide 4: 2025 Business Updates
2025 Business Updates
Slide 5: 2025 Achievements
ARCEX launch has been a resounding success; Empower BP pivotal study now underway; 2025 Achievements significant 2026 growth drivers in place Details in next slides Commercial launch Advancing pipeline Corporate Sold 117 ARCEX® Systems to > 80 US clinics Received FDA IDE approval for EMPOWER BP Rais
Slide 6: ARC-EX
ARC Brtproressiona | Oe March 2026 Webcast 6
Slide 7: ARC-EX 2025 Sales Acceleration
Sales increasing each quarter, with ARCEX now available in over ARCEX 2025 Sales 80 US clinics Acceleration 117 units sold 2025 sales, # of units sold (cumulative) >80 US clinics penetrated 70 units sold1 >50 US clinics penetrated 30 units sold1 10 units sold Q1 Q2 Q3 Q4 Limited US clinic launch Bro
Slide 8: Rapid ARC-EX US Clinic Penetration
As of 31 December 2025 Rapid adoption by US rehabilitation clinics, already 25% penetrated with purchase of at Rapid ARCEX US least one ARC-EX System Clinic Penetration Commercial validation Widespread adoption across 30 states >80 US clinics have already purchased at least one ARC-EX System ~25% of
Slide 9: Current US Sales Team Buildout
As of 06 March 2026 US field organization now fully deployed and productive, comprised of 100% Physical and Current US Sales Occupational Therapists Team Buildout Territories West Four Corners Red River North Central Ohio Valley South Mid Atlantic 1 Sales leader North East 8 Sales staff 6 Clinical s
Slide 10: European ARC-EX Launch Underway
As of 06 March 2026 Already rapid traction among European clinics, following CE Mark authorization in late 2025 European ARCEX Launch Underway First clinic sale in Q4 2025 ARCEX sold and delivered to clinics in NL, IT, UK, DE, and CH Note: Countries in which ARCEX clinic devices have been sold and d
Slide 11: Scientific Publications
Rare concurrent Nature and Nature Medicine publications detailing blood pressure feasibility study results and Scientific mechanism; publication on LIFT Home study results Publications An implantable system to A neuronal architecture Home-Based Noninvasive Spinal restore hemodynamic underlying auton
Slide 12: 2025 Capital Raise
Another well executed funding round, driven by high quality investors 2025 Capital Raise Over €50M in equity capital raised, supported by demand from high-quality, long-only and sector specialist investors Anchor investors were Ottobock, a global player in prosthetics, orthotics and exoskeleton tech
Slide 13: Corporate Update
Strengthened leadership and ability to scale with appointment of new Board Corporate Update Directors and senior executives Management Board Sean Sciara Ali Kiboro Shari O’Quinn Tim Denison Lucas Buchanan Chief Commercial Officer Chief Financial Officer Chief Clinical, Regulatory Non-Executive Direc
Slide 14: FY 2025 Results
FY 2025 Results
Slide 15: FY 2025 Financial Review
FY 2025 Financial EUR Million Review For the year ended, 31 December 2025 2024 Total Revenues & Other Income 5.4 1.7 Gross Profit 4.4 1.7 R&D Expenses (incl. Clinical & Regulatory & Patents) (18.0) (18.6) Marketing & Market Access Expenses (8.1) (3.4) Quality Assurance Expenses (2.4) (2.0) General &
Slide 16: FY 2025 Cash Update
Strong cash position of €68.1M at year end FY 2025 Cash Update Burn Ending Revenue €42.8M used Balance FY2025 €5.4M in FY 20251 during FY 2025 €68.1 M net cash2 as of 31 Dec 2025 1 Revenue includes grant and other income, 2 Net cash is defined as the sum of cash and cash equivalents and fixed term d
Slide 17: Q1 2026 US Commercial Trends
Q1 2026 US Commercial Trends
Slide 18: Q1 2026 Trends: VA Clinics
As of 06 March 2026 Nearly half of the 25 VA SCI-focused hubs have already adopted ARCEX Therapy Q1 2026 Trends: VA Clinics VA 15 Active clinics 1 44% of VA hubs penetrated 2 1 Penetrated 11 hubs and 4 spokes 2 Based on 25 VA hubs total March 2026 Webcast 18
Slide 19: Q1 2026 Trends: US Home Use
As of 06 March 2026 Strong initial ARCEX home use demand in VA and self-pay categories; patient access program to Q1 2026 Trends: be launched in Q2 for Workers Comp and Private US Home Use Pay Self-pay home use VA home use 18 Self-pay home units sold + purchase orders received 1 6 VA “Hub” SCI clini
Slide 20: Empower BP Update
Empower BP Update
Slide 21: ARC-IM
ARCIM March 2026 Webcast 22
Slide 22: Blood Pressure Unmet Need in SCI
Greater than 90% of patients treated for blood pressure instability continue to Blood Pressure experience symptoms Unmet Need in SCI Orthostatic Hypotension (OH) Autonomic Dysreflexia (AD) Low blood pressure tied to posture or postural Sudden, often dangerous rise in blood pressure in response to a
Slide 23: Empower BP Update
As of 31 March 2026 Study is gaining momentum, with first implant now completed and 10 sites now Empower BP Update activated First patient implanted 10 US sites activated Note: Map includes active centers and selected centers pending activation. For details, visit onwd.com/empower-bp March 2026 Webc
Slide 24: ARC-IM Blood Pressure Roadmap
Commercial launch continues to be anticipated in 2H 2028 ARCIM Blood Pressure Roadmap Pivotal trial & commercial launch 2026 2027 2028 2029 Enrollment and primary endpoint completion Follow-up Interim analysis Submission & approval Anticipated commercial launch March 2026 Webcast 26
Slide 25: 2026 Outlook
2026 Outlook
Slide 26: ARC-EX Demand Drivers
Unlocking new demand drivers in 2026 ARCEX Demand and 2027 Drivers US Clinics US Home EU & RoW ILLUSTRATIVE 2028+ Potential addition of a second ARCEX indication 2025 2026 2027 US clinic launch Additional US clinic sales (new and existing clinics) Also, initial US home use sales US VA home use sales
Slide 27: Upcoming Milestones and News Flow
Several important catalysts expected in the next 12 months Upcoming Milestones ARCEX ARCIM ARCBCI and News Flow ARCEX ARCEX ARCEX ARCEX First commercial clinic First commercial home First commercial home First commercial clinic sale (EU) use sale (US) use sale (EU) sale (ROW) Hand sensation & Hand s
Slide 28: Q&A
Q&A
Slide 29: Thank you!
Thank you! 31
Slide 30: Slide 30